Icos discontinues Phase III of LeukArrest

ICOS said that results from an interim analysis of its Phase III trial of LeukArrest to treat ischemic stroke "failed to meet the company's predefined criteria

Read the full 269 word article

How to gain access

Continue reading with a
two-week free trial.